{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"condition":["Neoplasm Metastasis","Colorectal Neoplasms"],"disease":["Neoplasm Metastasis","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2153900"],"location":["China"],"study_start_month":["10"],"keyword":["Chemotherapy","Liver metastasis","Avastin","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases","description":"In this study, the investigators assessed the effect of avastin in combination with chemotherapy in the treatment of RAS mutant-type, unresectable colorectal liver-limited metastases","dates":{"creation":"2013-10-15"},"accession":"2153900","cross_references":{"ClinicalTrials___gov":["NCT01972490"]}}